Anaeropharma Science



Target: Anaeropharma Science Inc.

Outline: Biopharma company aiming to launch a new drug in cooperation with the pharmaceutical industry, with the Drug


Delivery System (DDS) developed by Shinshu University as its core

Authorized investment: JPY 4.2 billion (maximum) Announcement date of investment: November 1, 2010



Investment Managerial support

Watervein Partners
Novartis
Seventure Partners
Shinsei Corporate
Investment
Mitsubishi UFJ Capital



Anaeropharma Science

Using Bifidobacteria to industrialize the technology for a Drug Delivery System (DDS) to deliver concentrated drug doses to affected areas


Dose of genetically engineered bifidobacteria administered. Bifidobacteria are anaerobic and prefer the characteristically low-oxygen environments found in solid cancer tissue

A dose of prodrugs is administered, which reacts with the enzymes in the bifidobacteria accumulated inside the cancer tissue, producing anti-cancer agents only in the affected area of solid cancer tissue Boosts the effectiveness of anti-cancer agents while mitigating side-effects

Technology transfer









Joint development

- Use Bifidobacteria based DDS as a development platform with the aim of meeting unmet medical needs
- Through joint support alongside private sector venture capital aim to generate domestic drug discovery success stories